Obsidian Will Present Amsoki-cel Data in November
Obsidian Therapeutics will share updated Phase 1/2 clinical results for its cell therapy at the 2026 SITC Annual Meeting.
Updated on Oct. 2, 2026 in Biotech
Live Poll
Is now a good time to increase investment in experimental cancer therapies like cell treatments?
Obsidian Therapeutics is set to present updated safety and efficacy data for amsoki-cel at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. The presentation, scheduled for November 7, 2026, will feature findings from 15 patients treated at the recommended phase 2 dose.
Why it matters
The upcoming data presentation provides essential updates on the clinical progress of this engineered tumor-infiltrating lymphocyte cell therapy. These results help clarify the potential of amsoki-cel as a future treatment option for patients with advanced melanoma.
The efficacy update features results from 15 patients treated with the therapy. Findings will be detailed in abstract number 566, with a separate trial-in-progress poster available under abstract number 570.
The players
Obsidian Therapeutics
This Cambridge, Massachusetts-based biotechnology company focuses on developing engineered cell therapies using protein-regulation technology.
The details
Obsidian Therapeutics utilizes proprietary protein-regulation technology to develop its engineered tumor-infiltrating lymphocyte cell therapies. Amsoki-cel is uniquely armored with membrane-bound IL15, and the company is currently conducting both a first-in-human study and the registration-enabling Agni-01 trial.
Timeline
November 4-8, 2026: The SITC 2026 Annual Meeting takes place in Phoenix, AZ.
November 7, 2026: Clinical data for amsoki-cel will be presented via poster sessions.
The Big Picture
This development follows the parameters and design goals established by the Agni-01 trial. The presentation of these results aligns with the company's broader trajectory of validating its protein-regulation technology in human clinical studies.
The study results provide insight into the potential efficacy of amsoki-cel for patients facing advanced melanoma. These findings are crucial for determining the future role of this therapy in clinical treatment regimens.
The takeaway
Clinical presentations like these are vital milestones for assessing the viability of novel cell therapies. Investors and healthcare providers should monitor these findings to understand the shifting landscape of oncology treatment options.
Further reading
Learn more about the latest industry developments in Biotech.
Live Poll
Is now a good time to increase investment in experimental cancer therapies like cell treatments?
